Astrazeneca plc
NASDAQ: AZN
$66.41
+$0.78 (+1.2%)
Real Time Data Delayed 15 Min.
AZN Articles
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Monday. Advanced Micro Devices Inc. (NYSE: AMD) raised to Neutral from Sell at...
Published:
Last Updated:
The three major US stock indexes opened lower this morning following a negative reaction by a government official to a weekend report that Germany would support a sovereign bond-buying plan for the...
Published:
Last Updated:
Jon OggThese are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Monday morning. Agrium Inc. (NYSE: AGU) named as Bull of the Day at...
Published:
Last Updated:
Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to...
Published:
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers...
Published:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
The three major US stock indexes opened sharply lower this morning following a tepid report on US job growth. The US economy managed to create just 80,000 jobs in June, below the consensus estimate...
Published:
Last Updated:
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. ...
Published:
Last Updated:
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around this diabetes treatment...
Published:
Last Updated:
The major US stock indexes opened flat this morning but started to move higher following the better-than-expected ISM report on manufacturing (our coverage here). Construction spending in the US was...
Published:
Last Updated:
Canaccord maintains its buy rating on Hologic (NASDAQ: HOLX) after it announced a buyout of Gen-Probe for $3.7. Canaccord also reiterated its buy rating on Watson Pharmaceuticals (WPI: NYSE)...
Published:
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company. It is one of the biggest public merger rumors out there. At least that is the belief of Wall...
Published:
Last Updated:
Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company. With another small-cap to mid-cap biotech and...
Published:
Last Updated:
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from...
Published: